Semler Scientific Files 8-K
| Field | Detail |
|---|---|
| Company | Semler Scientific, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 22, 2025 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
SEMLER SCIENTIFIC FILED AN 8-K. NO SPECIFIC DETAILS PROVIDED YET.
AI Summary
Semler Scientific, Inc. filed an 8-K on September 22, 2025, reporting other events and financial statements. The filing does not contain specific details on new agreements, acquisitions, or financial performance figures within the provided text.
Why It Matters
This filing indicates Semler Scientific is providing updates to the SEC, which could relate to ongoing business operations or financial reporting requirements.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate negative or positive financial disclosures.
Key Players & Entities
- Semler Scientific, Inc. (company) — Registrant
- September 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36305 (identifier) — Commission File Number
- 26-1367393 (identifier) — IRS Employer Identification No.
- 51 E Campbell Ave , Suite 107-D (address) — Principal executive offices
- Campbell (location) — City of principal executive offices
- CA (location) — State of principal executive offices
- 95008 (zip_code) — Zip code of principal executive offices
- ( 877 ) 774-4211 (phone_number) — Registrant's telephone number
FAQ
What specific events are being reported in this 8-K filing by Semler Scientific, Inc.?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items being reported, but the provided text does not detail the specific nature of these events.
When was the earliest event reported in this Form 8-K?
The earliest event reported is dated September 22, 2025.
What is Semler Scientific, Inc.'s principal executive office address?
The principal executive offices are located at 51 E Campbell Ave, Suite 107-D, Campbell, CA 95008.
What is Semler Scientific, Inc.'s Commission File Number?
Semler Scientific, Inc.'s Commission File Number is 001-36305.
What is the SIC code for Semler Scientific, Inc.?
The Standard Industrial Classification (SIC) code for Semler Scientific, Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
Filing Stats: 2,205 words · 9 min read · ~7 pages · Grade level 17.1 · Accepted 2025-09-22 09:20:56
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share SMLR The Nasdaq
Filing Documents
- tm2526607d1_8k.htm (8-K) — 46KB
- tm2526607d1_ex99-1.htm (EX-99.1) — 37KB
- 0001104659-25-091918.txt ( ) — 262KB
- smlr-20250922.xsd (EX-101.SCH) — 3KB
- smlr-20250922_lab.xml (EX-101.LAB) — 33KB
- smlr-20250922_pre.xml (EX-101.PRE) — 22KB
- tm2526607d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On September 22, 2025, Semler Scientific, Inc., or Semler Sci, and Strive, Inc., or Strive, issued a joint press release announcing their entry into an Agreement and Plan of Merger, or the Merger Agreement, providing for the acquisition of Semler Sci by Strive in an all-stock transaction subject to the terms and conditions set forth in the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Semler Sci is updating previous guidance regarding new 510(k) clearance from the U.S. Food and Drug Administration, or FDA, for expanded labeling of QuantaFlo, which is intended as an aid in the diagnosis of other cardiovascular diseases. Semler Sci currently anticipates the new 510(k) clearance by the end of the second quarter of 2026 at the earliest. Cautionary Statement Regarding Forward-Looking Statements Certain statements herein and the documents incorporated herein by reference may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended, and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Strive and Semler Sci, respectively, with respect to the proposed transaction, the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company's future financial performance, the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses. Such
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed with this report: Exhibit No. Description 99.1 Joint Press Release dated September 22, 2025 104 The cover page from this current report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SEMLER SCIENTIFIC, INC. Date: September 22, 2025 By: /s/ Renae Cormier Name: Renae Cormier Title: Chief Financial Officer ( Principal Financial Officer and Principal Accounting Officer)